Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry

dc.contributorHáskóli Íslandsen_US
dc.contributorUniversity of Icelanden_US
dc.contributor.authorGudbjornsson, Bjorn
dc.contributor.authorGeirsson, Árni J.
dc.contributor.authorKrogh, Niels Steen
dc.contributor.departmentLæknadeild (HÍ)en_US
dc.contributor.departmentFaculty of Medicine (UI)en_US
dc.contributor.schoolHeilbrigðisvísindasvið (HÍ)en_US
dc.contributor.schoolSchool of Health Sciences (UI)en_US
dc.date.accessioned2018-09-19T15:53:55Z
dc.date.available2018-09-19T15:53:55Z
dc.date.issued2018-05
dc.description.abstractObjective: To explore differences in response to a low dosage regimen of infliximab with an escalating dosage in comparison to a standard dosage of etanercept and adalimumab in patients with psoriatic arthritis (PsA). Methods: Biologically naïve PsA patients who were beginning anti-TNF-α therapy were selected from the ICEBIO registry. Demographics and clinical differences were compared in four treatment groups: infliximab <4 mg/kg; infliximab >4 mg/kg; etanercept or adalimumab at baseline and on follow-up (6 and 12 months, last visit). The Kruskal–Wallis rank sum test was used for comparison of the groups and the Wilcoxon test to compare the two infliximab dosage regimens. Results: One hundred and eighty-five patients (61% female) were identified; 84 patients received infliximab, 66 etanercept, and 35 adalimumab. A total of 19% of the patients treated with infliximab escalated their dosage ≥4 mg/kg. No significant differences were observed at baseline in respect to visual analog scale (VAS) pain, VAS fatigue, Health Assessment Questionnaire, C-reactive protein (CRP), numbers of swollen or tender joints, or Disease Activity Score (DAS) 28-CRP values. A similar treatment response was observed in all four treatment groups on follow-up. Conclusion: In respect to treatment effects, a low dosage of infliximab with possible escalating dosage is acceptable for the majority of PsA patients who are in need of biological treatment.en_US
dc.description.sponsorshipThe study was partly funded by a study grant from The Icelandic Society for Rheumatology.en_US
dc.description.versionPeer Revieweden_US
dc.format.extent13-19en_US
dc.identifier.doi10.2147/PTT.S161522
dc.identifier.issn2230-326X
dc.identifier.journalPsoriasis: Targets and Therapyen_US
dc.identifier.urihttps://hdl.handle.net/20.500.11815/849
dc.language.isoenen_US
dc.publisherDove Medical Press Ltd.en_US
dc.relation.ispartofseriesPsoriasis: Targets and Therapy;8
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPsoriatic arthritisen_US
dc.subjectBiological treatmenten_US
dc.subjectRoutine careen_US
dc.subjectCinical nationwide registryen_US
dc.subjectSóríasisen_US
dc.subjectSlitgigten_US
dc.subjectMeðferðen_US
dc.titleLow starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registryen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dcterms.licenseThe full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.en_US

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Hleð...
Thumbnail Image
Nafn:
PTT-161522-low-starting-dosage-of-infliximab-with-possible-escalating-d_050318.pdf
Stærð:
335.97 KB
Snið:
Adobe Portable Document Format
Description:
Publisher´s version (útgefin grein)

Undirflokkur